This open-label Phase 1 study evaluated the pharmacokinetics (PK) and safety of ETR in the presence of fluconazole (moderate CYP2C9 and CYP3A4 inhibitor; strong CYP2C19 inhibitor), gemfibrozil (strong ...

Effective from January 1, 2001, standard fluconazole prophylaxis for all VLBW infants has been instituted in our NICU: thus, a comparison was also made among the 2 different periods (July 1997 ...

Regardless of whether the presumed etiology is infectious or noninfectious, the treatment of breast inflammation is consistent. The focus is on reversing milk stasis, maintaining milk supply, and ...

changes in blood cells, such as thrombocytopenia (a decrease in the number of platelets which causes easy bruising and nasal bleeding), leucopoenia (a decrease of white blood cells which may cause ...